The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II randomized study comparing proton craniospinal irradiation with photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis.
Jonathan T. Yang
Stock and Other Ownership Interests - Nanocan Therapeutics
Consulting or Advisory Role - AstraZeneca; Debiopharm Group; Galera Therapeutics; Nanocan Therapeutics
Research Funding - AstraZeneca; Kazia Therapeutics; X-RAD Therapeutics
N. Ari Wijetunga
No Relationships to Disclose
Elena Pentsova
No Relationships to Disclose
Suzanne L. Wolden
No Relationships to Disclose
Robert J. Young
No Relationships to Disclose
Denise Correa
No Relationships to Disclose
Zhigang Zhang
No Relationships to Disclose
Junting Zheng
No Relationships to Disclose
Allison Betof Warner
Consulting or Advisory Role - BluePath Solutions; Instil Bio; Iovance Biotherapeutics; Nanobiotix; Novartis; Pfizer; Shanghai Jo'Ann Medical Technology
Helena Alexandra Yu
Consulting or Advisory Role - AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines; C4 Therapeutics; Cullinan Oncology; Daiichi Sankyo; Janssen
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Blueprint Medicines; Cullinan Oncology (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Janssen Oncology (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Astellas Pharma
Mark G. Kris
Consulting or Advisory Role - AstraZeneca; Janssen; Pfizer
Travel, Accommodations, Expenses - Genentech
Andrew David Seidman
Honoraria - AstraZeneca; Genentech/Roche; Genomic Health; Gilead Sciences; Immunomedics; Lilly; Novartis
Consulting or Advisory Role - BeyondSpring Pharmaceuticals; Eisai; Genentech/Roche; Gilead/Forty Seven; Immunomedics; Lilly; Novartis; Pfizer
Speakers' Bureau - Genentech/Roche; Genentech/Roche; Genomic Health; Gilead Sciences; Lilly; Novartis/Pfizer
Research Funding - Bayer; Nektar (Inst); Odonate Therapeutics (Inst)
Rachna Malani
No Relationships to Disclose
Andrew Lin
No Relationships to Disclose
Lisa Marie DeAngelis
Consulting or Advisory Role - Sapience Therapeutics
Nancy Y. Lee
Consulting or Advisory Role - Merck; Merck Serono; Mirati Therapeutics; pfizer; Roche/Genentech; Sanofi
Research Funding - AstraZeneca; Pfizer (Inst)
Simon N. Powell
No Relationships to Disclose
Adrienne Ann Boire
Patents, Royalties, Other Intellectual Property - Boire A and J Massagué, inventors. Sloan Kettering Institute, assignee. Modulating Permeability Of The Blood Cerebrospinal Fluid Barrier. United States Provisional Application No.: 62/258,044. November 20, 2015. (Inst); Boire A, Chen Q and J Massagué, inventors. Sloan Kettering Institute, assignee. Methods for Treating Brain Metastasis. United States 10413522, awarded September 17, 2019. (Inst); Boire A, inventor. Sloan Kettering Institute, assignee. Methods of Treating Leptomeningeal Metastasis. United States Provisional Application No.: 63/052,139. Jul 15, 2020 (Inst)
(OPTIONAL) Uncompensated Relationships - Evren Technologies